Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes

Shots:

• The PIONEER 6 study results involve assessing oral Semaglutide vs PBO in 3,183 patients with type 2 diabetes at high risk of cardiovascular events
• The PIONEER 6 study results: met its 1 EPs i.e non-inferiority for MACE; cardiovascular death events (0.9% vs 1.9%); non-fatal stroke (0.8% vs 1.0%); non-fatal myocardial infarctions (2.3% vs 1.9%); presented at ADA 79th Scientific Sessions and published in NEJM
• Semaglutide is an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of T2D, developed using Novo Nordisk’s protein-acylation technology, and is administered using an injection device

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: Bridgetnmiller.Weebly